A comparative evaluation of levamisole in leprosy

Area of Science:

• Dermatology
• Infectious Diseases
• Pharmacology

Background:

• Leprosy, a chronic infectious disease, requires multifaceted treatment strategies.
• Leprosy reactions, particularly Type 1 and Type II, necessitate prompt and effective management.
• Dapsone (DDS) is a standard treatment, but adjunct therapies are explored for managing reactions and improving outcomes.

Purpose of the Study:

• To evaluate the efficacy of levamisole as an adjunct therapy in managing leprosy reactions.
• To compare the effectiveness of levamisole plus DDS with clofazimine plus DDS and DDS alone in leprosy patients.
• To assess the impact of these treatment regimens on clinical improvement and reactional episodes.

Main Methods:

• A study involving 90 adult leprosy patients was conducted at the Institute Hospital of Varanasi, India.
• Patients were divided into three groups: levamisole plus DDS, clofazimine plus DDS, and DDS alone.
• Levamisole was administered at 150 mg daily for three consecutive days, repeated every 12 days, over a six-month period.

Main Results:

• Levamisole demonstrated a faster reduction in both Type 1 and Type II leprosy reactions compared to clofazimine.
• Clinical improvement in non-reactionary leprosy cases was comparable across all three treatment groups.
• Minor side effects were observed in patients receiving levamisole and clofazimine.

Conclusions:

• Levamisole is a potentially effective therapeutic option for expediting the resolution of leprosy reactions.
• The addition of levamisole or clofazimine to DDS does not significantly alter clinical improvement in non-reactionary leprosy.
• Further research may explore optimal dosing and long-term efficacy of levamisole in leprosy management.